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Abstract 
Polymersomes have the potential to be applied in targeted alpha radionuclide therapy, while in addition 
preventing release of recoiling daughter isotopes. In this study, we investigated the cellular uptake, post 
uptake processing and intracellular localization of polymersomes. Methods: High-content microscopy 
was used to validate polymersome uptake kinetics. Confocal (live cell) microscopy was used to elucidate 
the uptake mechanism and DNA damage induction. Intracellular distribution of polymersomes in 3-D was 
determined using super-resolution microscopy. Results: We found that altering polymersome size and 
concentration affects the initial uptake and overall uptake capacity; uptake efficiency and eventual plateau 
levels varied between cell lines; and mitotic cells show increased uptake. Intracellular polymersomes 
were transported along microtubules in a fast and dynamic manner. Endocytic uptake of polymersomes 
was evidenced through co-localization with endocytic pathway components. Finally, we show the 
intracellular distribution of polymersomes in 3-D and DNA damage inducing capabilities of 213Bi labeled 
polymersomes. Conclusion: Polymersome size and concentration affect the uptake efficiency, which 
also varies for different cell types. In addition, we present advanced assays to investigate uptake 
characteristics in detail, a necessity for optimization of nano-carriers. Moreover, by elucidating the uptake 
mechanism, as well as uptake extent and geometrical distribution of radiolabeled polymersomes we 
provide insight on how to improve polymersome design. 
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Introduction 
Targeted alpha therapy (TAT) is considered as 
treatment option for various tumours, such as bladder 
cancer, brain tumours, neuroendocrine tumours, and 
prostate cancer [1, 2]. Alpha particles have high linear 
energy transfer (LET) and therefore result in a higher 
relative biological effect (RBE), compared to low-LET 
radiation. The range of alpha particles is up to 100 μm 
in water, while it is even more limited in tissue [3]. 
These distances only span a few cells, thereby limiting 
damage to surrounding healthy tissue [4]. In current 
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experimental therapy settings, short-lived 
radionuclides require rapid targeting for efficient 
dose delivery to target cells [5]. Long-lived 
radionuclides can overcome these limitations, but are 
often part of a longer decay chain which leads to the 
release of recoiling daughter isotopes. Recoiling 
daughter isotopes break free from their targeting 
vehicle, such as antibodies and peptides, and can 
distribute freely in the body, potentially causing harm 
to healthy tissue [6, 7]. This problem can be solved by 
the use of nano-carriers, e.g. liposomes. While the 
retention of the mother nuclides in liposomes is up to 
98%, the retention of the recoiled daughter isotopes is 
less than 20% [8]. Low retention makes liposomes 
poor carriers of high-LET radionuclides with multiple 
alpha emitting isotopes in the decay chain. 
Nano-carriers composed of polymers, such as 
dendrimers, polymeric particles, nano-gels and 
micelles are more robust and are thereby more 
effective in retaining the daughter isotopes compared 
to other nano-carriers [9-11].  
Polymersomes (PMs), formed through 
self-assembly of amphiphilic block copolymers, 
combine the possibility to counter the recoil problem 
and have highly versatile adjustable properties, 
making them attractive candidates for customized 
high-LET radionuclide [12, 13]. Nano-carriers are 
commonly known to be delivered at the tumor site via 
the enhanced permeability and retention (EPR) effect 
[14, 15]. This effect is mostly observed in rapidly 
growing solid tumors and their high demand for 
oxygen and nutrients. This high demand causes 
underdeveloped and leaky vasculature in and around 
the tumor. PM therapy can exploit this phenomenon, 
which allows passive PM transfer to tumor areas via 
the blood circulation. Variation in size could provide 
beneficial effects on circulation times and mechanical 
filtration [16]. Recent reports show that variations in 
charge and degree of attached polyethylene glycol 
(PEG) affect PM uptake, circulation time and 
clearance pathways [12, 16-19]. In addition, 
intra-tumoral injections show high retention in tumor 
tissue, which could indicate intracellular uptake of 
PMs and not accumulation in the extracellular matrix 
[19, 20]. 
Although the uptake of other nano-carriers in 
cells has been documented, to our knowledge, no 
reports show the cellular and biological uptake 
mechanism of PMs. Recently, several reports show the 
use of PMs for TAT in both in vitro and in vivo 
experiments, suggesting that PMs can be used in a 
therapeutic setting [21, 22]. The short range and 
high-LET of alpha particles requires prolonged 
localization close to the target cells, which can be 
reached if PMs are geographically fixed by cellular 
uptake. A better understanding of the precise uptake 
mechanism and geometrical distribution of the PMs is 
crucial to understand how they exert their cell-killing 
effect in different cell populations. With the use of 
high-content, confocal (live cell) and super-resolution 
imaging we evaluate cellular uptake kinetics and 
post-uptake processing of PMs. 
Materials & Methods 
Polymersome preparation and 
characterization 
PMs with average diameters of 60 and 80 nm 
were prepared according to the ‘inverse 
nanoprecipitation method’ [23]. In short, the 
amphiphilic diblock copolymers (polybutadiene-d- 
polyethyleneoxide (PBd1800PEO900)) were dissolved in 
1 mL acetone in a 4 ml glass vial (Rotilabo®), using a 
Vortex-Genie 2 (Scientific industries, Inc.) to obtain a 
20 mg/mL block copolymer concentration. The 
solution was filtered using a 0.20 µm syringe filter 
(PFTE, unsterile, Rotilabo®). Afterwards, 50 vol % 
PBS was added using an Aladdin programmable 
syringe pump (World Precision Instruments, LLC) 
and a 2 mL Injekt™ syringe (B Braun) under magnetic 
stirring on a Standard Stirrer (VWR®) at 300 rpm. The 
remaining acetone was evaporated using a Rotary 
Evaporation at 30 degrees for at least 15 minutes. 
Samples of size 400 nm were prepared according to 
the ‘direct dissolution method’ [24]. In short, 10 
mg/mL block copolymer was added to a 1 mM DTPA 
PBS solution at pH 7.4, and stirred for a week. 
Subsequently, the PMs were extruded to the required 
diameter by passing them several times through 
polycarbonate filters with cut-off membrane of 400 
nm. PMs used for radiolabeling were passed through 
a 30 cm x 0.5 cm (L x r) Sephadex G 25 M size 
exclusion column (Sigma-Aldrich) to remove excess 
DTPA. 
The size and shape of the PMs were determined 
by Dynamic Light Scattering (DLS) and Cryogenic- 
Transmission Electron Microscopy (Cryo-TEM). The 
DLS apparatus consisted of a JDS Uniphase 633 nm 35 
mW lasers, an ALV sp 125 s/w 93 goniometer, a fiber 
detector and a photon counter (Perkin Elmer). An 
ALV-500/epp correlator was used to obtain the size 
correlation function. Scattering cells of 3 mL with an 
internal diameter of 12 mm were immersed in a 
temperature regulated toluene bath. The intensity 
auto-correlation function was determined at 90 
degrees. The autocorrelation function was analyzed 
by the Contin method [10] and the radius of the PMs 
was determined using Einstein-Stokes equation. 
Cryo-TEM characterization was done as 
described before [11]. In short, 3 μL of a 10 mg/mL 
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PMs solution was deposited on a holey carbon film 
(Quantifoil 2/2) supported on a TEM grid. The 
sample was blotted and vitrified by rapid immersion 
in liquid ethane (Leica EM GP version 16222032), and 
subsequently immersed in liquid nitrogen. A 
cryo-transfer holder (Gatan model 626) was used to 
transfer to a Jeol JEM 1400 TEM and images were 
acquired at an acceleration voltage of 120 keV. For 
diameter determination, 30-50 images were made of 
PM samples and measured using FIJI [25]. 
Fluorescent labeling and Quantification 
Membrane labeling of PMs was done using a 
fluorescent moiety attached to a lipophilic tail with 
optimal excitation at 551 nm and emission at 567 nm 
(PKH26, Sigma-Aldrich) or with optimal excitation 
wavelength at 490 nm and emission at 502 nm 
(PKH67, Sigma-Aldrich) according to manufacturer 
protocol. In short, 20 μL of PMs (10 mg/mL) and 5 μL 
PKH-dye (working concentration of 2.5E-5 M) were 
separately diluted in provided Diluent C to 100 μL 
end volume. Hereafter, the two solutions were mixed 
and incubated for 10 minutes. After the 10-minute 
incubation step the PMs are separated from unbound 
PKH dye using an Exosome Spin Column 
(Sigma-Aldrich) according to manufacturer protocol. 
Columns allow buffer exchange on the PMs or to 
remove any low molecular weight (MW ≤ 3000) 
mixtures from the preparation. In short, provided 
spinning columns were solidified using 650 μL PBS 
and incubated for 10 minutes. Excess PBS was 
removed by centrifuging the column for 2 minutes at 
750 x g. 100 μL of labeled PM solution was then added 
to the column and centrifuged for 2 minutes at 750 x g, 
leaving only labeled PMs in Diluent C solution. PKH 
labeled PMs were quantified by an newly developed 
confocal fluorescent microscopy assay (EVQuant) 
[26]. In short, fluorescently labeled particles were 
immobilized in a transparent gel and imaged using an 
Opera Phenix High Content Screening (HCS) System 
(Perkin Elmer) and analyzed using Harmony 5.4 
(Perkin Elmer). Absolute concentration of in-gel 
immobilized particles is derived from the number of 
detected fluorescent particles in the calibrated volume 
of the imaged region.  
Radioactive labeling 
Elution of 213Bi was performed as described 
before [27]. The elution mixture was composed of 0.3 
mL, 0.2 M HCl and 0.3 mL 0.2 M NaI and pumped 
through the generator at a flowrate of 0.15 mL/min 
into a vial containing 0.12 mL of 4 M sodium acetate 
buffer. 
For PM labeling, 700 μL of 213Bi was added to a 
mixture of 10 μL 20 mM tropolone and 100 μL 100 
mM Hepes. This solution was incubated for 15 min at 
RT allowing the 213Bi to bind with tropolone. 
Subsequently, 200 μL 1 mM DTPA encapsulated PMs 
with a concentration of 1E13 fluorescently labeled 
PMs/mL was added to the mixture and incubated for 
1 hour. Next, the activity was measured by using a 
NaI detector before and after the column purification 
of the solution to calculate the loading efficiency of 
the PMs. Column purification was done using a 
Sephadex G 25 M column (Sigma-Aldrich) to remove 
excess DTPA. 213Bi retention was similar to previously 
reported labeling methods for 111In and 225Ac [10]. 100 
μL 10 mM DTPA was added to 0.5 mL polymersomes 
loaded with 213Bi and equilibrated for 15 minutes at 
room temperature. Subsequently, the solution was 
passed through a Sephadex PD10 column to separate 
the Bi-DTPA complexes from the polymersomes. The 
elution was portioned per mL and the 213Bi activity in 
each eluted fraction was determined by dividing the 
activity detected in the polymersomes by the total 
activity before separation. At the dose used, no 
difference in size and physical characteristics was 
expected [28]. 
Cell Culture 
U2OS (Human Bone Osteosarcoma), J774A.1 
(Mouse Balb/c Monocyte Macrophage) and CA20948 
(Rat Pancreatic Cancer) cell lines were cultured in 
Dulbecco’s modified Eagle’s medium supplemented 
with 1% Penicillin/Streptomycin and 10% Fetal Calf 
Serum. The C5Ro (Human fibroblast) cell line was 
cultured in Hams’ F10 culture medium supplemented 
with 1% Penicillin/Streptomycin and 15% Fetal Calf 
Serum. DU145 (Prostate Cancer, CNS Metastasis) and 
PNT2C2 (Prostate Epithelial) cell lines were cultured 
in RPMI 1640 medium supplemented with 1% 
Penicillin/Streptomycin and 5 or 10% Fetal Calf 
Serum. Mouse embryonic fibroblasts (MEFs) were 
cultured in 50% Dulbecco’s modified Eagle’s medium 
and 50% Hams’ F10 medium supplemented with 1% 
Penicillin/Streptomycin and 10% Fetal Calf Serum. 
All cells were incubated at 37 ºC in a water saturated 
atmosphere with 5% CO2. 
High-content microscopy 
To visualize and quantify PM uptake, cells were 
seeded (10.000-20.000 cells per well) in 96-wells plates 
(Sensoplate, Greiner Bio) in duplicates and cultured 
for 24h. Cells were incubated with PKH26-labeled 
PMs of different sizes (60, 80 and 400 nm in diameter) 
and different concentrations (1E10, 2E10, 5E10 or 1E11 
PMs/mL) for 1, 2 and 3 hours prior to fixation (4% 
PFA, 30 min). Cells were washed with PBS and 
plasma membrane was labeled using PKH67 
(Sigma-Aldrich) according to the manufacturers 
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protocol. In short, fixed cells were incubated in 50 μL 
Diluent C containing PKH67 (2 μL/mL). Samples 
were stored in 200 μL PBS containing Hoechst 
(1:10000) for nuclear staining. Fluorescent images 
were acquired using an Opera Phenix HCS system 
(Perkin Elmer). For each well, 25 Images were 
acquired using a 20x objective (NA = 0.4) and the 
appropriate laser lines and emission filters (Hoechst; 
ex. 405 nm - em. 435-480 nm, PKH67; ex. 488 nm – em. 
500-550 nm and PKH26; ex. 561 nm – em. 570-630 nm. 
Images were analyzed by the Opera Phenix analysis 
software (Harmony 5.4) to quantify the number of 
PMs per cell.  
Confocal (live cell) microscopy 
To capture dynamic events of PM uptake and 
processing, cellular uptake of PMs was analyzed by 
high-speed Spinning disk microscopy (Nikon 
Ti-Eclipse and ROPER FRAP3D unit). To study PM 
uptake in living cells, we used a PNT2C2 cell line 
stably expressing CAAX-GFP [29]. For microtubule 
imaging PNT2C2 cells were transiently transfected 
using Tubulin-YFP (YFP-β-tubulin expression 
construct was kindly provided by Dr. Galjart, 
Erasmus University Medical Center). For PM uptake 
experiments, 1E11 PKH26-labeled PMs/mL were 
added to cells and image acquisition was started 
using intervals of 500/1000 ms. PM movement speed 
was analyzed using the TrackMate plugin in FIJI [30]. 
For co-localization experiments PNT2C2 cells 
were transiently transfected with Rab4a-YFP 
(early-endosomes, [31]) or incubated with 
LysoTracker Red (lysosomes, Invitrogen). Rab4a-YFP 
transfected cells were incubated with PKH26-labeled 
PMs and LysoTracker Red labeled cells were 
incubated with PKH67-labeled PMs. Cells were 
incubated with 1E11 PMs/mL for 30 minutes, washed 
with PBS and fixed at time points 30, 60, 90, 120, 180, 
240, 300 and 360 minutes after starting PM incubation. 
Fluorescent laser scanning confocal microscopy 
(CLSM510, Zeiss) was used to capture at least 10 cells 
per time point for both endocytic markers. 
Co-localization analysis was performed using FIJI and 
a customized FIJI macro. In short, in every image both 
PMs and endocytic compartments in transfected cells 
were identified and masked based on thresholding 
the two fluorescent channels. Subsequently, the 
number of PMs overlapping with endocytic 
compartments was divided by the total number of 
PMs to calculate the percentage of co-localization for 
each image. 
To visualize the DNA-damage induced by 
radioactive loaded PMs, U2OS cells were transiently 
transfected with 53BP1-GFP (marker for DNA 
double-strand breaks, full length 53BP1) [32]. 
Transfected cells were treated with 213Bi- and PKH26 
labeled PMs. 213Bi was used as damaging agent and 
PKH26 was used for visualization of PMs. Cells were 
treated for 3 hours, washed with PBS and fixed. 
Confocal microscopy (Leica SP5) was used to capture 
cells with and without PMs. The numbers of DNA 
damage clusters were manually quantified. To 
investigate the fate of 53BP1 clusters induced by alpha 
particle irradiation, U2OS cells were transiently 
transfected with mScarlet-53BP1. Truncated 53BP1 
(t53BP1, [33]) was fused to mScarlet and inserted into 
a homemade PiggyBac construct. Plasmid and 
construct information is available on request. 
Transfected cells were externally irradiated using 
previously described methods [34]. Live cell imaging 
was performed on a confocal microscope (Leica SP5) 
overnight (16 hours). Number of cells going through 
mitosis was manually quantified.  
Super resolution imaging and distance 
distribution analysis 
For intracellular distribution analysis of 
intracellular PMs, structured illumination microscopy 
(SIM) was used. PNT2C2 cells were incubated with 
1E10 PMs/mL for 2 hours. SIM imaging was 
performed on a Zeiss Elyra PS1 with an Andor iXon 
DU 885 EMCCD camera (Carl Zeiss AG, Oberkochen, 
Germany) using 488, 561 and 642 nm laser excitation 
with 100 ms exposure times. Samples were 
illuminated with a spatial line pattern that was shifted 
in five phases and rotated in five orientations. The 
raw images were reconstructed into a high‐resolution 
3D‐dataset using the Zeiss 2012 PS1 ZEN software. 
Reconstruction was done using default settings.  
The location of each PM in an image was 
determined using the find maxima algorithm in FIJI. 
Distribution of PM distance to the nucleus was 
measured for each cell using intensity profiles of the 
lines between the center of the nucleus and all PMs. 
The distance was defined as the length from the PM 
up to the onset of the nuclear staining. Cutoff distance 
was determined according to the decay chain of 213Bi 
to 209Pb, mainly emitting an alpha particle of 8 MeV 
[35].  
Results 
Kinetics of polymersome uptake in different 
cell-types 
The PMs used in our experiments are composed 
of polybutadiene (PBd) and polyethylene oxide (PEO) 
block co-polymers and were formed in solution by 
‘inverse nanoprecipitation’ (for PMs <100 nm) or 
‘direct dissolution’ (for PMs >100 nm). PMs were 
characterized by Cryo-TEM and DLS, which showed 
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that the obtained PMs had size distributions of 60 (±8), 
80 (±11) and 400(±7) nm in diameter (Figure 1A). To 
investigate the cellular uptake mechanism of PMs we 
used different cell types, U2OS (bone osteosarcoma), 
PNT2C2 (prostate epithelial), DU145 (prostate cancer) 
and J774A.1 (mouse macrophage, from now on 
referred to as J774). Exploiting the bi-layered 
membrane of PMs we employed PKH-dyes for in vitro 
fluorescent tracking. PKH-dyes are composed of 
intense fluorescent moieties attached to long 
lipophilic tails. Diffusion of the lipophilic tails in the 
bi-layer, leaves the fluorescent moiety exposed for PM 
tracking. Using both PKH26 (Excitation 551 
nm/Emission 567 nm) and PKH67 (Excitation 
490/Emission 502) we labeled PMs suitable for 
multiple color combinations. The concentration of 
detected PMs was measured by the recently 
developed nanoparticle quantification assay EVQuant 
[26]. The EVQuant assay revealed a labeling efficiency 
of up to 80% for PKH dyes and concentrations of up to 
7.64E13 PMs/mL. Pilot experiments in mouse 
embryonic fibroblasts (MEFs) showed clustered PM 
influx using wide-field microscopy, from 6 hours post 
incubation onwards to 48 hours (Figure 2). Due to this 
observation we chose for earlier time points and 
confocal microscopy in the uptake assays for optimal 
quantification. For uptake experiments the cells were 
incubated with PMs (80±11 nm) and fixed at 1, 2 or 3 
hours post incubation. No background signal at 
control conditions was observed and PM uptake did 
not affect cell morphology. Over the course of 3 hours, 
PMs gradually entered the intracellular 
compartments of all cell types (Figure 1B). Most 
notably, the distribution of PMs at 3 hours showed a 
perinuclear positioning in U2OS cells compared to a 
random distribution in PNT2C2 cells.  
 
 
Figure 1. Uptake kinetics of polymersomes. (A) Cryo-TEM analysis of PMs dissolved in water (B) U2OS, PNT2C2, DU145 and J774 cells labeled with PKH67 
(green) as membrane marker were incubated with 80 (±11) nm PMs labeled with PKH26 (red). Cells were fixed at indicated time points and imaged using a 
high-throughput Opera Phenix system. (C) Quantitative analysis of 60 (±8) nm (red), 80 (±11) nm (blue) and 400 (±7) nm (black) sized PM uptake in U2OS cells. (D) 
Uptake analysis of 80 (±11) nm sized PMs in PNT2C2 cells at 1 (red), 2 (blue) or 5 (black) times the original concentration used for uptake experiments. (E) 
Quantitative analysis of uptake in U2OS (Red), J774 (blue), PNT2C2 (green) and DU145 (black) cells incubated with 80 (±11) nm sized PMs. Error bars indicate SEM, 
technical replicates. N>1000 cells per condition. 
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Figure 2. Polymersome uptake. MEFs were incubated with 80 (±11) nm sized PKH26 labeled PMs. Cells were fixed at indicated time points and imaged using a 
wide field epifluorescent microscope (Axio Imager D2, Zeiss).  
 
To determine the influence of PM size and 
concentration on the uptake kinetics in different cell 
types we employed high-content microscopy for 
quantitative measurements. As differences in 
nano-particle size could influence cellular uptake 
kinetics, we first compared uptake rates of 60, 80 and 
400 nm diameter PMs in U2OS cells. In a 96-well plate, 
10,000 U2OS cells per well were incubated with 2E10 
PKH26-labeled PMs/mL for 1, 2 and 3 hours. Cells 
were washed with PBS and the cell membranes and 
nuclei were stained by PKH67 and Hoechst, 
respectively. Faster uptake kinetics were observed for 
PMs with 60 nm in diameter compared to 80 and 400 
nm. Cells incubated with 60 nm PMs reached a higher 
plateau level at 3 hours post addition compared to 
both 80 and 400 nm sized PMs (Figure 1C). Next, 
various concentrations of initial stock concentrations 
of PMs were assessed for uptake using PNT2C2 cells 
using the same high-content microscopy set-up. Cells 
were incubated for 15, 30, 60, 90, 120 and 180 minutes 
with 1E10 PMs/mL, 2E10 PMs/mL, and 5E10 
PMs/mL of 80 nm diameter PMs. PM uptake is linear 
with the concentration we used (an average of 2.5 
times more PMs at 120 min, between 2E10 and 5E10 
PMs/mL, Figure 1D).  
Finally, to assess possible differences among cell 
lines, four different cell lines were incubated with 
1E11 PMs/mL. Comparison between different cell 
lines revealed similar uptake kinetics over time for 
each of the four cell lines reaching a plateau after 2 
hours, possible caused by cellular restrictions of 
further uptake. Interestingly, the U2OS and PNT2C2 
cell lines and the J774 and DU145 cell lines showed a 
difference in plateau levels (Figure 1E). Altogether, 
we found that uptake of PM was 2-fold higher for 60 
nm PMs compared to 80 nm and 400 nm PMs. 
Moreover, uptake increased linearly from 1E10 to 
5E10 PMs/mL. Finally, the maximum number of PM 
taken up differed among cell lines.  
Uptake and dynamic processing of 
polymersomes  
In previous high-content screens we observed 
that PM uptake already occurs in the first 15 minutes 
after addition. We therefore wanted to capture the 
immediate response of cells after addition of PMs. To 
visualize the cellular membrane and transport across 
this membrane we used a PNT2C2 cell line which 
stably expresses CAAX-GFP. The CAAX-motif is a 
target for prenylation [36], and when attached to the 
GFP protein, it will target GFP to the plasma 
membrane. CAAX-GFP is therefore a fluorescent 
marker of the cell membrane, which was used for 
live-cell imaging of PMs entering the cytoplasmic 
compartment of cells. Imaging with intervals of 20 
min was started immediately after additions of PMs. 
Interestingly, cells undergoing mitosis (the two upper 
cells) showed dramatically higher uptake of PMs than 
cells in other phases of the cell cycle (lower cells, 
movie S1, scale bar: 20 µm).  
To shorten the time interval, we used high-speed 
spinning disk microscopy which allowed recording of 
events with minimal time intervals as short as 500 ms. 
Captured movies are represented using stills of 
several time points (Figure 3A). At t=0 s recording 
started, several seconds after addition of PMs. The 
first captured image already showed that PMs entered 
the cells, indicated by the white arrow. Within 28 
seconds the indicated PM entered the cytoplasmic 
compartment and moved toward the center of the cell 
(t=71 s and movie S2, scale bar: 10 µm). Internalized 
PMs were surrounded by green signal, indicated by 
the yellow arrow and in the close up square. Since 
CAAX-GFP is localized as an integral part of the 
plasma membrane we explain this by assuming that 
internalization of PMs occurs with concurrent 
internalization of the cellular membrane. This 
indicates that uptake could occur via an endocytic 
pathway [37]. The short time interval imaging 
revealed highly dynamic and directional movement 
of PMs after uptake (Movie S3, scale bar: 10 µm). 
Directionality of intracellular movements could point 
to processing of PMs by cell components such as 
microtubules [38].  
We therefore expressed Tubulin-YFP in PNT2C2 
cells to image the microtubules inside PNT2C2 after 
PM uptake. Again, cells were incubated with 
PKH26-labeled PMs and spinning disk microscopy 
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was used for imaging of microtubules. The dynamic 
and directional movements of internalized 
PKH26-labeled PMs (white arrow) localized at 
microtubules (Figure 3B and movie S4, scale bar: 10 
µm). The linear displacement movement speeds 
through the cytoplasm reached intracellular velocities 
up to 1 μm/s (Figure 3 C and D). Interestingly, 
velocity showed periodic peaks over-time, indicating 
‘pause’ steps during the process. Co-localization with 
microtubules and periodic movements already shown 
for early-endosomes generates a second indication of 
endocytic uptake of PMs [39]. 
Analysis of endocytic uptake of polymersomes 
For further analysis of the intracellular fate of 
PMs we used co-localization studies. With the use of 
specific proteins or makers that label early-endosomes 
(Rab4a-YFP) and lysosomes (Lysotracker red) we 
investigated the co-localization of endocytic bodies 
and intracellular PMs. Rab4a-YFP expression 
constructs were transiently transfected into PNT2C2 
cells. Rab4a-YFP (Excitation 514/Emission 525) was 
combined with PKH26 labeled PMs and Lysotracker 
red (Excitation 550/Emission 590) was combined with 
PKH67 labeled PMs. In a pulse-chase experiment we 
incubated cells with PMs (1E11 PMs/mL) for 30 
minutes, washed with PBS and refreshed with 
complete medium. Treated cells were fixed at 30, 60, 
90, 120, 180, 240 and 360 minutes after PBS-wash. At 
least 10 cells per time point were imaged for 
co-localization analysis of PMs compared to marked 
endocytic pathway components (Figure 3E, typical 
examples at 30 and 300 minutes after PBS wash). 50% 
of PMs (PKH26) co-localized with early-endosomes 
(Rab4A-YFP) at 30 minutes, which declined to 10% 
within 5 hours. In contrast, co-localization between 
Lysotracker red (lysosomes) and PKH67 labeled PMs 
increased to 60% within 6 hours after treatment 
(Figure 3F). These results showed the transition of 
PMs throughout the maturation of early-endosomes 
to lysosomes in the endocytic pathway. In addition, 
spinning disk microscopy of PNT2C2 cells transiently 
expressing Rab4a-YFP (early-endosomes) showed 
clear merging of Rab4a-YFP labeled organelles 
containing PMs, indicating fusion of early-endosomes 
to late-endosomes/lysosomes (Movie S5, scale bar: 10 
µm). We conclude that in vitro uptake of PMs is 
mediated through the endocytic pathway, where PMs 
enter the cell via early-endosomes and ultimately 
accumulate in lysosomes.  
 
 
Figure 3. Rapid uptake, microtubule processing and co-localization of the endocytic pathway of polymersomes. PNT2C2 cells stably expressing 
either CAAX-GFP or transiently expressing Tubulin-YFP were incubated with 80 (±11) nm sized PMs (PKH26 labeled, red) and imaged using Spinning Disk Confocal 
Microscopy. (A) Stills of PM uptake, showing attachment (0s), uptake (28-47s) and intracellular processing (47-71s) of PMs, indicated by white arrows. CAAX-GFP 
component (in green) encircles PMs inside the cell, indicated by yellow arrows. Scale bar represents 5 µm. (B) Stills of PM processing. Microtubule labeled by 
Tubulin-YFP, green. Arrows indicate PMs moving along microtubules. T=0 represents the start of imaging. Scale bar represents 5 µm. (C) Representative image of 4 
PMs which were tracked over-time. Cell membrane is represented by the dashed line. Scale bar represents 5 µm. (D) Velocity of 4 PMs over 30 seconds in a cell. PMs 
were tracked using Manual Tracking in FIJI. (E) DU145 cells (expressing Rab4a-YFP or incubated with Lysotracker-Red) were incubated with 80 (±11) nm PMs 
(containing PKH26 or 67) and fixed at various time points. Rab4a co-localization and Lysotracker co-localization at 30 and 300 min. Scale bar represents 25 µm. (F) 
Quantification of PM co-localization with early endosomes and lysosomes in time. Error bars indicate SEM, N=10 cells per time point. 
Nanotheranostics 2020, Vol. 4 
 
http://www.ntno.org 
21 
High-resolution analysis of intracellular 
distribution of polymersomes 
The position of PMs is highly dynamic during 
the processing of endosomes to lysosomes. The 
dynamic distribution of PMs throughout this process 
could greatly influence the efficiency of energy 
deposition of alpha particle irradiation [40]. The 
information of the exact distance of PMs to nuclei at 
certain time points could be of great use, considering 
the short path-length of alpha particles. With the use 
of Structured Illumination Microscopy (SIM) we 
determined the position of intracellular PMs with 
high precision and evaluated per nucleus the number 
of PMs which were in range to deposit alpha particle 
radiation to the nucleus. We treated PNT2C2 cells 
with PKH26 labeled 80 nm PMs for 2 hours, washed 
with PBS, fixed, and stained the nuclei with DAPI. 
Using 3D analysis, we drew lines between centers of 
nuclei and PMs (Figure 4A and movie S6). By 
measuring the intensity profile of the nuclear staining 
on the straight lines we calculated the distance 
between the edge of the nucleus and all PMs in a 
single image. We use the drop of sirDNA signal as 
indication of the edge of the nucleus (Figure 4B.1). 
Distances between the edge of the nucleus to the PM 
coordinate was defined as ‘distance to nucleus’. By 
calculating all PM to nucleus distances we generated a 
distance distribution (Figure 4B.2). The histogram 
shows that most PMs (1008 of 1091, 92%) are within 
the range of the supposed alpha particle path length 
(<40 μm, red line, median: 17.7 µm). We conclude that 
many PMs can contribute to effective alpha particle 
irradiation of cell nuclei in a 2-D setting. To test this, 
the efficacy with which DNA damage could be 
induced could be investigated using radiolabeled 
PMs with alpha particle emitting radionuclides. 
213Bi labeled polymersomes damage nearby 
nuclei of U2OS cells after uptake 
Positioning of PMs in the cytoplasmic 
compartment of cells could be crucial for the effective 
DNA damage induction when irradiation is used. We 
used the DNA damage marker p53 binding protein 1 
(53BP1) fused to GFP to visualize DNA damage 
inflicted by radioactivity in U2OS cells [41]. In 
addition, we used PKH26 and PKH67 to visualize 
PMs and the plasma membrane, respectively. Typical 
examples of 53BP1-GFP control conditions and after 
external alpha particle irradiation are used as 
reference to PM treated samples. A few small 
53BP1-GFP clusters were present when no DNA 
damage is induced (yellow arrows, Figure 4C.1) 
compared to numerous and large 53BP1-GFP clusters 
after alpha particle induced DNA damage (white 
arrows, Figure 4C.2). 
To investigate DNA damage inflicted by alpha 
particles, originated from radiolabeled PMs, we used 
213Bi as radionuclide. Radioactive labeling of PMs 
showed efficiencies up to 49.2% for 213Bi and the 
activity measured was 372 kBq/mL. U2OS cells were 
treated with 2E12 213Bi-PMs/ml (372 kBq) for 3 hours, 
washed with PBS and fixed. Confocal imaging was 
used to determine the spatial distribution of double 
strand breaks (53BP1-GFP clusters) and PMs after 
treatment (Figure 4D). Nuclei of cells with 
intracellular PMs (Figure 4D.2, unfilled arrow) 
showed increased 53BP1-GFP clusters, compared to 
nuclei of cells with no intracellular PMs (Figure 4E.1). 
Quantification showed a 2-fold increase of 53BP1-GFP 
foci in the nucleus if 213Bi labeled PMs are in the 
cytoplasmic compartment of U2OS cells (Figure 4E). 
These results are comparable with the external alpha 
particle irradiation experiments, indicating direct 
DNA damage induction by intracellular 213Bi labeled 
PMs but no apparent DNA damage induction to 
nuclei in close vicinity. To investigate the fate of alpha 
particle irradiated U2OS cells at later time points we 
used live-cell imaging. U2OS cells transiently 
transfected with mScarlet-t53BP1 (a truncated version 
of 53BP1) were externally irradiated with alpha 
particles and imaged immediately. Snapshots of both 
non-irradiated and irradiated cells show that both go 
through cell division (Figure 4F and G, movie S7). 
Interestingly, alpha particle induced DNA damage 
did not prevent cell division. However, quantification 
showed that cells not hit by alpha particles showed 
significantly more dividing cells than cells that did got 
hit (32% vs 3.2%, Figure 4H). We conclude that 
213Bi-PMs induced DNA damage to U2OS nuclei 
when PMs were present in the cell, comparable with 
DNA damage when external alpha-irradiation was 
used. When PMs were not intracellular, no apparent 
induction of DNA damage was observed. Cells hit by 
alpha particles are possibly delayed or restricted to go 
through mitosis compared to cells that did not get hit. 
Moreover, our improved understanding of PM 
internalization assists in accurate prediction of 
nuclear DNA damage induction by radionuclide 
carrying PMs in targeted cells. 
Discussion 
PMs have high potential in targeted alpha 
radionuclide therapy, while in addition the recoil 
problem of high-LET radionuclides could be solved. 
In this study we investigated the cellular uptake and 
intracellular processing of PMs to elucidate the 
uptake characteristics of PBd-PEO based PMs. Our 
work demonstrates that altering PM size and 
concentration affects the initial rate of uptake and 
overall uptake capacity. In addition, PM uptake varies 
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between cell lines and cells undergoing mitosis have 
an increased PM uptake. High-speed live cell 
microscopy shows that PMs enter cells, co-localize 
with membrane components, and are transported 
along microtubules in a dynamic fashion. Evidence 
for endocytic uptake of PMs was obtained from 
co-localization of PMs and endocytic pathway 
compartments. Moreover, we show that the 
intracellular distribution and the DNA damage 
induced by 213Bi labeled PMs can best be described by 
a model that takes into account only damage caused 
by PMs in their cell of residence. 
 
 
Figure 4. Polymersome distance distribution of 231Bi labeled polymersomes and DNA damage induction. PNT2C2 cells were incubated for 2 hours 
with 80 (±11) nm sized PKH26 labeled PMs. (A) 3D representation of the distance calculation between PM and the center of a nucleus. White arrow indicates the 
position of one PM. The intensity profile on the right shows the intensity of nuclear staining measured on that straight line. Distance of PM to nucleus is the 
determined as the line size between the clear drop of nucleus signal to PM position. (B) Example of an intensity profile measured on a straight line in between a PM 
and the center of a nucleus. Red line indicates the threshold for the edge of the nucleus (B.1). Overall distance distribution of PMs to nucleus (N=1091). Red line 
shows the relevant 40 µm distance cut off (B.2). (C) U2OS cells expressing 53BP1-GFP as DNA-damage marker. Typical examples of U2OS cells expressing 
53BP1-GFP at control levels (C.1) and after alpha-particle irradiation (C.2). Yellow arrows indicate endogenous 53BP1-GFP foci and white arrows indicate DNA 
damage caused by alpha-particle irradiation. (D) U2OS cells expressing 53BP1-GFP were incubated with PMs (empty arrow) labeled with 231Bi (0.15 MBq) for 3 hours. 
Membrane was labeled with PKH67. Yellow arrows endogenous 53BP1-GFP foci (D1). White arrows indicate alpha-particle induced DNA damage. Empty arrow 
indicates radiolabeled PMs (D1). (E) DNA damage quantification. 7 cells without (-) or with (+) intracellular PMs (total = 14 cells) were evaluated for amount of 53BP1 
foci. Error bars show SEM. Scale bar represents 10 µm. (F) U2OS cells expressing mScarlet-t53BP1 as DNA-damage marker. Typical examples of cells going through 
mitosis without DNA damage (F) and after alpha-particle irradiation (G). Arrows indicate the 2 daughter cells after mitosis. Time points indicate time in between snap 
shots. Scale bar represents 5 µm. (H) Quantification of mitosis. N= 38 for non-irradiated cells (-), N = 95 for irradiated cells (+) Error bars show SEM. 
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PM uptake and efficiency by macrophages (J774) 
was similar to prostate cancer cells (DU145) but less 
than osteosarcoma (U2OS) and prostate-epithelial 
(PNT2C2) cells (Figure 1B). Cell size or shape could 
have impact on the uptake rate and plateau levels of 
PM uptake. Larger cells have more surface area for 
PMs to enter and less membrane tension which leads 
to increased uptake efficiency [42]. Unexpectedly, 
macrophages did not show disproportionately faster 
or increased uptake compared to cancer or epithelial 
cell lines. This is in contrast to several in vivo reports 
where high levels of liver and spleen uptake was 
observed. Uptake in these organs is explained by the 
presence of macrophages, for example Kupffer cells in 
the liver [19, 43, 44]. A possible explanation for the 
difference in the data obtained in vivo versus the data 
from cultured cells could be the immortalization of 
J774 cells. Immortalized cell lines could acquire 
altered properties over time in cell culture [45]. 
Including primary cells, for example harvesting 
Kupffer cells from the liver, could provide a more 
realistic setting [46]. On the contrary, specific uptake 
by tumour-associated macrophages could induce 
polarization, which is thought to be beneficial for 
immune-therapies [47]. 
In addition to cell type or size, cell-cycle state 
could also have an impact on PM uptake. Live-cell 
imaging shows increased PM uptake at the point of 
mitosis. The alteration of the cell membrane during 
mitosis could allow PMs to enter the cells [48]. In 
addition, the change of cell shape during mitosis is 
accompanied by recycling membrane components to 
intracellular compartments [49]. The increased uptake 
of PMs by dividing cells suggests enhanced uptake in 
frequently dividing tumor cells, important for 
therapeutic approaches using PMs [50]. The uptake of 
PMs we observe in our experiments and encounter in 
previous literature suggests that endocytosis is the 
most probable pathway by which PMs enter cells [51]. 
Co-localization experiments confirmed that PMs enter 
the cell and reside in early-endosomes, eventually 
ending up in lysosomal compartments. In addition, 
intracellular processing of PMs shows co-localization 
with microtubules and bi-directional movement 
patterns and speeds of 0.2 to 1 μm/s for 4 measured 
PMs. The measured velocities are comparable with 
previously reported values of 0.6 μm/s [52, 53]. Since 
the PMs we employed are non-biodegradable we 
assumed that they remain in the cytoplasm for longer 
periods than we have investigated and form bulky 
lysosomal compartments [54]. While we show the 
co-localization with endocytic compartments during 
PMs entry and processing, the exact endocytic 
pathway remains to be elucidated. The use of 
haploid-screening could be used to determine 
important genes for PMs uptake, shown in similar 
experiments for viral entry and chemotherapeutic 
sensitization [55, 56].  
Aside from PM uptake, knowledge of 
intracellular localization is desired for 
(micro)dosimetry calculations. Simulations have 
shown that radionuclides in close vicinity of the 
nucleus have higher RBE compared to radionuclides 
at the membrane [40]. Theoretically, the amount of 
DNA damage is dependent on the position of the 
Bragg peak [57]. Radiolabeled PMs localized close to 
the nucleus should therefore have a higher chance to 
induce DNA damage due to geometric 
considerations. Peri-nuclear localization and 
lysosomal aggregation after uptake of 
non-biodegradable nano-carriers is suggested and 
described in literature [58]. This was observed in 
U2OS cells already 1 hour after PM addition, but not 
in PNT2C2 cells, which show a more random 
distribution (Figure 1B). Our data suggest a random 
distribution of multiple PMs within 40 µm of 
surrounding nuclei in a 2-D setting in PNT2C2 cells 
(Figure 4B). In addition, PMs are being trafficked 
throughout the cytoplasm via microtubules in the 
investigated time span and eventually accumulate in 
the lysosomes (Figures 3B and E, Movies S2 and S3). 
This movement and positioning is dependent on time, 
but also on cell type (Figure 1B, [59]). The continuous 
movement makes a direct correlation of PM location 
and the induction of DNA damage very challenging. 
In addition, recent work highlights the need for active 
targeting of PMs, especially in the presence of a 
tumour [60]. This could possibly change the uptake 
and processing dynamics of PMs, both in vitro and in 
vivo [61-63].  
However, the analysis presented here could 
function as a prerequisite for the interpretation of 2-D 
experiments for comparison to 3-D in vitro systems, 
where radiation from neighbouring cells is much 
higher [21]. In addition, in current experimental 
set-up, the small amount of PMs translates to a small 
amount of alpha particles that are being emitted and a 
low delivered dose to cells. Using 213Bi, we provided 
preliminary insight of possible therapeutic benefit. 
However, the singular alpha emission of 213Bi, does 
not provide enough information of the benefit of 
intracellular PMs. 225Ac, for example, has multiple 
alpha emissions in its decay chain. The use of 225Ac 
has seen therapeutic potential in glioma models [21]. 
For future studies, the use of 225Ac might be more 
relevant to investigate the benefit of geographically 
fixing radiolabeled PMs intracellularly. Moreover, our 
observations suggest that in a 2-D setting, most of the 
alpha particles go out of plane, not hitting a nucleus. 
This makes it hard to explain an one-to-one ratio 
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correlation of DNA damage with the intracellular 
PMs responsible of emission. This demonstrates the 
impact of localization and uptake efficiency of PMs 
labeled with alpha particle emitting radionuclides.  
In conclusion, PM uptake is mediated via 
endocytosis and is particle size, concentration, and 
cell type dependent. Our findings suggest that PM 
and, in theory, other nano-carrier uptake and 
processing can differ significantly between cell lines. 
This difference will influence the effective DNA 
damage induction by the radionuclides encapsulated 
by PMs. Analysing uptake characteristics using the 
assays presented in this study will help to provide 
crucial information, such as DNA damage inducing 
capabilities and effective uptake. In addition, the 
assays provide techniques to study the effect of 
specific characteristics of nano-carriers, for later 
therapeutic use. Future experiments with PMs and 
other nano-carriers will benefit from the advanced 
analysis presented here and results should be 
considered for increased efficiency of optimization for 
new nano-carriers. 
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